Responses
Regular and young investigator award abstracts
Clinical trials in progress
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results
Compose a Response to This Article
Other responses
No responses have been published for this article.
